1 2

Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves cross-ancestry prediction

- 3
- 4 Thomas J Hoffmann^{1,2,*}, Rebecca E Graff^{2,*}, Ravi K Madduri³, Alex A Rodriguez³, Clinton L
- 5 Cario⁴, Karen Feng⁵, Yu Jiang^{2,4}, Angi Wang^{6,7}, Robert J Klein⁸, Brandon L Pierce^{9,10,11}, Scott
- 6 Eggener^{12,11,13}, Lin Tong⁹, William Blot¹⁴, Jirong Long¹⁴, Louisa B Goss¹⁵, Burcu F Darst¹⁵,
- 7 Timothy Rebbeck¹⁶, Joseph Lachance¹⁷, Caroline Andrews¹⁶, Akindele O Adebiyi¹⁸, Ben
- 8 Adusei¹⁹, Oseremen I Aisuodionoe-Shadrach²⁰, Pedro W Fernandez²¹, Mohamed Jalloh²²,
- 9 Rohini Janivara¹⁷, Wenlong C Chen²³, James E Mensah²⁴, Ilir Agalliu²⁵, Sonja I Berndt²⁶, John P
- 10 Shelley²⁷, Kerry Schaffer²⁸, Mitchell J Machiela²⁶, Neal D Freedman²⁶, Wen-Yi Huang²⁶,
- 11 Shengchao A Li²⁶, Phyllis J Goodman²⁹, Cathee Till²⁹, Ian Thompson³⁰, Hans Lilja^{31,32}, Dilrini K
- 12 Ranatunga³³, Joseph Presti³⁴, Stephen K Van Den Eeden³⁴, Stephen J Chanock²⁶, Jonathan D
- 13 Mosley^{35,27}, David V Conti^{6,7}, Christopher A Haiman^{6,7}, Amy C Justice^{36,37}, Linda Kachuri^{4,38,**},
- 14 John S Witte^{4,38,5,39,**}
- 15 1. Institute for Human Genetics, University of California San Francisco, San Francisco, CA, 16 USA 17 Department of Epidemiology and Biostatistics, University of California San Francisco, 18 San Francisco, CA, USA 19 Data Science and Learning Division, Argonne National Laboratory, Argonne, IL, USA 20 4. Department of Epidemiology and Population Health, Stanford University School of 21 Medicine, Stanford, CA, USA 22 Department of Biomedical Data Science, Stanford University, Stanford, CA, USA 23 Center for Genetic Epidemiology. Department of Population and Preventive Health 24 Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, 25 USA 7. Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern 26 27 California, Los Angeles, CA, USA 28 Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount 29 Sinai, New York, NY, USA 30 9. Department of Public Health Sciences, University of Chicago, Chicago, IL, USA 10. Department of Human Genetics, University of Chicago, Chicago, IL, USA 31 32 11. Comprehensive Cancer Center, University of Chicago, Chicago, IL, USA 33 12. Department of Urology, University of Chicago, Chicago, IL, USA 34 13. Department of Surgery, University of Chicago, Chicago, IL, USA 35 14. Division of Epidemiology, Vanderbilt University Medical Center, Nashville, TN, USA 36 15. Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA 37 16. Dana Farber Cancer Institute, Harvard School of Public Health, Boston, MA, USA 38 17. School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA 39 18. Department of Community Medicine, College of Medicine, University of Ibadan, Ibadan, 40 Nigeria 41 19. 37 Military Hospital, Accra, Ghana

| 42 43 | 20. College of Health Sciences, University of Abuja, Abuja, Nigeria; Cancer Science Centre Abuja, Abuja, Nigeria: University of Abuja Teaching Hospital, Abuja, Nigeria |
|----------|--|
| 44 | 21 Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South |
| 45 | Africa |
| 46 | 22. Hospital General Idrissa Pouve, Dakar, Senegal; Ecole Doctorale, Univesite Iba Der |
| 47 | Thiam de Thies |
| 48 | 23. Strengthening Oncology Services Research Unit, Faculty of Health Sciences, University |
| 49 | of the Witwatersrand, Johannesburg, South Africa; Sydney Brenner Institute for |
| 50 | Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, |
| 51 | Johannesburg, South Africa; National Cancer Registry, National Institute for |
| 52 | Communicable Diseases a Division of the National Health Laboratory Service, |
| 53 | Johannesburg, South Africa |
| 54 | 24. Korle-Bu Teaching Hospital and University of Ghana Medical School, Accra, Ghana |
| 55 | 25. Dept of Epidemiology and Population Health, and Dept of Urology, Albert Einstein |
| 56 | College of Medicine, New York, NY, USA |
| 57 | 26. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, |
| 58 | USA |
| 59 | 27. Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, |
| 60 | TN, USA |
| 61 | 28. Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, |
| 62 | TN, USA |
| 63 | 29. SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research |
| 64 | Center, Seattle, WA, USA |
| 65 | 30. CHRISTUS Santa Rosa Medical Center Hospital, San Antonio, TX, USA |
| 66 | 31. Departments of Pathology and Laboratory Medicine, Surgery, Medicine, Memorial Sloan |
| 67 | Kettering Cancer Center, New York, NY, USA |
| 68 | 32. Department of Translational Medicine, Lund University, Malmö, Sweden |
| 69 | 33. Kaiser Permanente Research Bank, Oakland, CA, USA |
| 70 | 34. Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA |
| 71 | 35. Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN, |
| 72 | |
| 73 | 36. Veterans Administration Connecticut Healthcare System, West Haven, Connecticut, |
| 74 75 | |
| 75 70 | 37. Department of Internal Medicine and Yale University School of Public Health, Yale |
| 76 77 | School of Medicine, New Haven, Connecticut, USA |
| 70 | 38. Staniord Cancer Institute, Staniord University School of Medicine, Staniord, CA, USA |
| ΙŎ | 39. Department of Genetics (by courtesy), Stanford University, Stanford, CA, USA |
| 79 | *These authors contributed equally to this work. |
| 80 | **These authors jointly supervised this work. |
| 81 | Correspondence should be addressed to: J.S.W. (jswitte@stanford.edu) and L.K. |
| o∠ 83 | (เหลงานเาษรเล่าแปน.ยนน) |
| 05 | |

85 Abstract

- 86 We conducted a multi-ancestry genome-wide association study of prostate-specific antigen
- 87 (PSA) levels in 296,754 men (211,342 European ancestry; 58,236 African ancestry; 23,546
- 88 Hispanic/Latino; 3,630 Asian ancestry; 96.5% of participants were from the Million Veteran
- 89 Program). We identified 318 independent genome-wide significant (p≤5e-8) variants, 184 of
- 90 which were novel. Most demonstrated evidence of replication in an independent cohort
- 91 (n=95,768). Meta-analyzing discovery and replication (n=392,522) identified 447 variants, of
- 92 which a further 111 were novel. Out-of-sample variance in PSA explained by our genome-wide
- 93 polygenic risk scores ranged from 11.6%-16.6% in European ancestry, 5.5%-9.5% in African
- 94 ancestry, 13.5%-18.2% in Hispanic/Latino, and 8.6%-15.3% in Asian ancestry, and decreased
- 95 with increasing age. Mid-life genetically-adjusted PSA levels were more strongly associated with
- 96 overall and aggressive prostate cancer than unadjusted PSA. Our study highlights how
- 97 including proportionally more participants from underrepresented populations improves genetic
- 98 prediction of PSA levels, offering potential to personalize prostate cancer screening.

100 Introduction

101 Prostate-specific antigen (PSA) is a protein encoded by the *KLK3* gene and secreted by the

- 102 prostate gland^{1–3}. PSA levels are often elevated in those with prostate cancer (PCa); however,
- 103 elevated levels can also be caused by other factors, such as benign prostatic hyperplasia
- 104 (BPH), local inflammation or infection, prostate volume, age, and germline genetics^{4–8}. PSA
- screening for PCa was approved by the Food and Drug Administration in 1994, but it is unclear
- if the benefits for PCa-specific mortality reduction outweigh the harms from overdiagnosis and
 treatment of clinically insignificant disease^{9–12}. Previous work estimates 20-60% of screen-
- 108 detected PCas are overdiagnoses (i.e., PCa that would not otherwise clinically manifest, or
- result in PCa-related death¹³), other work has suggested that 229 individuals would need to be
- 110 invited to screen and 9 would need to be diagnosed to prevent one death¹⁴, and the United
- 111 States¹⁵, Canada¹⁶, and the United Kingdom¹⁷ recommend against universal population-based
- screening. If PSA levels could be adjusted for an individual's predisposition in the absence of
- 113 PCa, the specificity (to reduce overdiagnosis) and sensitivity (to prevent more deaths) of
- 114 screening could be improved.
- 115
- 116 Twin studies estimate PSA heritability at 40-45%^{18,19}, and genome-wide heritability estimates at
- 117 25%-30%²⁰ suggesting that incorporating genetic factors may improve screening. Recent work
- 118 from our group based on 85,824 European ancestry and 9,944 non-European ancestry men
- found that genetically-adjusted PSA (i.e., the PSA measure inflated or deflated due to an
- 120 individual's genetic variants) most improved the discrimination of PSA screening for aggressive
- 121 tumors²⁰. In that work, we identified 128 genome-wide significant variants that explained up to
- 122 7% of PSA variation in European ancestry, suggesting that many more PSA loci remain.
- 123 Genome-wide polygenic risk scores (PRSs) explained up to 10% in European ancestry;
- however, the PRSs were less predictive in other groups, especially African ancestry (1-3%).
- 125 Additional variant discovery with larger, more diverse cohorts could provide novel insights into
- 126 the genetic architecture of PSA and further improve PCa screening.
- 127

128 Results

129 Composition of discovery and replication cohorts

- 130 Our discovery population consisted of 296,754 men without PCa from 9 cohorts: 211,342
- 131 European ancestry (71.2%), 58,236 African ancestry (19.6%), 23,546 Hispanic/Latino (7.9%),
- and 3,630 Asian ancestry (1.2%). None had been included in previous PSA GWASs. We
- 133 present genotype platform details in **Table S1**, demographics in **Table S2**, and quality control
- 134 (QC) metrics in **Table S3**. The pooled mean age at PSA measurement across the discovery
- 135 cohorts was 57.4 (standard deviation [SD]=9.6), and the pooled median PSA was 0.84. The
- 136 Million Veteran Program (MVP) comprised 96.5% of the discovery cohort. For replication, we
- 137 utilized results from 95,768 independent individuals from previous work²⁰, including 85,824
- 138 European ancestry, 3,509 African ancestry, 3,098 Hispanic/Latino, and 3,337 Asian ancestry
- 139 individuals (**Table S3**). **Figure 1** summarizes our analytical workflow and describes cohort
- 140 ancestry compositions.
- 141

142 Discovery GWAS analysis of PSA-associated variants

143 In our discovery cohorts, we identified 318 independent genome-wide significant variants (264 144 European, 51 African, 17 Hispanic/Latino, and 2 Asian) in a multi-ancestry analysis of log-145 transformed PSA levels (Figure 2, Figure S1, Table S4, Table S5) that used multiple reference 146 panels to account for different ancestries (see Methods). Among them, 184 independent 147 variants selected by mJAM²¹ were novel (see **Methods**). Of the novel variants, 57 replicated at 148 a Bonferroni level (p<0.05/184=0.00027, same direction of effect on PSA), an additional 80 replicated at p<0.05 (and the same direction), 43 demonstrated the same effect direction (but 149 150 p>0.05), and four showed no indication of replication (effect in the opposite direction). On 151 average, compared to the non-replicated variants, the replicated variants had slightly larger 152 effect sizes (mean β =0.30 versus 0.27) and were slightly more precise (mean standard 153 error=0.0039 versus 0.0042).

154

155 Of the 184 variants that were novel in the multi-ancestry analysis, 112 were genome-wide 156 significant in the European ancestry discovery cohort, eight were genome-wide significant in the 157 African ancestry cohort, and none were genome-wide significant in Asian or Hispanics/Latino 158 individuals (likely due to low sample size; Figure S2). Of the eight in African ancestry 159 individuals, only two variants were frequent enough (see Methods) to be assessed in other 160 ancestry groups: rs2071041 (ITIH4; BAfrican=0.0237, 95% CI=0.0152-0.0322, pAfrican=4.9e-8) that 161 was also genome-wide significant in European ancestry individuals (β_{European}=0.0180, 95% 162 CI=0.0124 to 0.0235, p_{European}=2.6e-10, minor allele frequency (MAF)=23.7%), and rs1203888 163 (LINC00261; β_{African}=-0.0423, 95% CI=-0.0539 to -0.0307, p_{African}=8.7e-13) that was not 164 significant in European ancestry individuals (p>.05, MAF=0.8%). The latter variant showed 165 similar magnitude of effect but was not Bonferroni significant in discovery Hispanic/Latino 166 individuals (B_{Hispanic/Latino}=-0.0748, 95% CI=-0.120 to -0.0297, p_{Hispanic/Latino}=0.0012, MAF=3.1%) 167 and was not significant in discovery Asian ancestry (p>.05, MAF=3.5%) or the replication 168 cohorts (p>.05) (Table S4). The remaining six African ancestry variants were too rare to be 169 assessed in European ancestry individuals. The variant rs184476359 (AR, multi-ancestry 170 discovery β=-0.0590, 95% CI=-0.0774 to -0.0406, p=3.4e-10; replication β=-0.0870, 95% CI=-171 0.1370 to -0.0371, p=6.3e-4) was common in African ancestry individuals (MAF=17.7%), less 172 common in Hispanic/Latinos (MAF=1.1%), and not adequately polymorphic to be imputed in 173 Asian individuals. Three variants in genes that encode PSA (rs76151346, β_{African}=0.0821, 95%) 174 CI=0.0577 to 0.107, p_{African}=4.6e-11, *KLK3*; rs145428838, β_{African}=0.224, 95% CI=0.165 to 0.284, p_{African}=1.4e-13, *KLK3*; rs182464120 β_{African}=-0.213, 95% CI=0.278 to 0.147, p_{African}=2.0e-10, 175 176 KLK2) exclusively imputed in African ancestry individuals (all MAF<5%, two <1%) did not exhibit 177 strong evidence of replication in African ancestry individuals(p>0.05). The remaining two 178 variants identified in African ancestry (rs7125654, $\beta_{African}$ =-0.384, 95% CI=-0.0489 to -0.0279, 179 p_{African}=7.0e-13; rs4542679, β_{African}=0.0422, 95% CI=0.0288 to 0.0557, p_{African}=7.9e-10), were 180 more common (MAF>5%) but also did not replicate (p>0.05). Further, rs7125654 (TRPC6) was 181 less common in Latinos, but more common in Asian ancestry, and rs4542679 (RP11-345M22.3) 182 was less common in Latinos and not adequately polymorphic in Asians. 183 184 We next tested for effect size differences across ancestry groups for the 184 novel variants.

185 Only one variant, rs12700027 (BRAT1/LFNG, I²=84.8, p=0.00019), demonstrated heterogeneity

186 that was Bonferroni-significant (p<0.05/184=0.00027). The variant had a strong discovery effect

- 187 in European ancestry individuals (β =0.0327, 95% CI=0.0247 to 0.0407, p=1.2e-15, MAF=0.10),
- but was not significant in other groups (African ancestry β =0.0131, 95% CI=-0.0190 to 0.0452,
- 189 p=0.42, MAF=0.021; Asian β =-0.176, 95% CI=-0.0203 to 0.0797, p=0.027, MAF=0.021;
- 190 Hispanic/Latino β =-0.0102, 95% CI=-0.0326 to 0.0121, p=0.37, MAF=0.120). In our replication
- 191 cohort, the variant nominally (i.e., p<0.05) replicated (p=0.0065, β =0.0175, 95% CI=0.00491 to
- 192 0.0302; European ancestry p=0.003, β =0.0327, 95% CI=0.0247 to 0.0407) and showed no 193 statistically significant evidence of differences across ancestry groups (I²=0.0, p=0.44), although
- statistically significant evidence of differences across ancestry groups (1 = 0.0, p=0.44), although
 sample sizes for detecting differences were smaller.
- 195
- 196 In-silico assessment of potential functional features revealed that 20 of the novel variants
- 197 (10.8%) were prostate tissue expression quantitative trait loci (eQTLs), and another 65 (35.3%)
- 198 were eQTLs in other tissues (**Table S4**). Five novel variants were missense and predicted to be
- deleterious, with Combined Annotation Dependent Depletion (CADD) scores >20 (**Table S4**):
- rs11556924 in ZC3HC1, which regulates cell division onset; rs74920406 in ELAPOR1, a
- transmembrane protein; rs2229774 in *RARG*, a gene in the hormone receptor family;
- rs113993960 (delta508) in *CFTR*, a causal mutation for cystic fibrosis²²; and rs2991716 upstream
- of LOC101927871. An additional 11 variants were predicted to have high pathogenicity (CADD scores >15;**Table S4**).
- 205

206 *Replication analysis of previously-reported variants in the discovery cohort*

- 207 When we tested 128 previously identified variants²⁰ in our discovery cohort, 106 (82.8%) 208 replicated at a genome-wide significance level, an additional 15 replicated (11.7%) at a
- 209 Bonferroni level (p<0.05/128=0.00039), an additional 6 replicated at p<0.05 (4.7%), and one
- 210 variant flipped effect direction (Table S6). Replication was highest for European ancestry, likely
- 211 due to sample size, with 94 variants (73%) reaching genome-wide significance, an additional 22
- variants (17.2%) meeting a Bonferroni-corrected level, and 8 (6.3%) additional variants meeting
- 213 p<0.05 (**Table S6**). Replication rates within African ancestry, our next largest group, were lower:
- 214 16 (12.5%) were genome-wide significant, 26 others (20.3%) met a Bonferroni level, an
- additional 39 (30.5%) had p<0.05, 32 additional (25.0%) were in the same direction, and 15
- 216 (11.7%) were in the opposite direction. Estimated rates were similar for Hispanic/Latino and
- 217 lowest for Asian populations. Lastly, 16 of the 128 known variants showed heterogeneity across
- 218 the four groups (Bonferonni corrected p<0.05/128=0.00039).
- 219

220 Joint meta-analysis of discovery and replication cohorts

- In the multi-ancestry analysis including the discovery and replication cohorts, we identified 447 independent variants (409 European, 56 African, 22 Hispanic/Latino, 6 Asian, including 46 in >1 group; **Figure 3, S1**; **Table S7**, **S8**). Among the 111 variants that were novel even relative to discovery alone, none showed evidence of ancestry effect size differences
- 225 (p>0.05/111=0.00045). Fifty-six (50.4%) of the 111 were genome-wide significant in European
- ancestry individuals, but none were genome-wide significant in a non-European ancestry group
- 227 (**Table S8**). Allele frequencies and effect sizes of the novel variants largely followed those
- expected by power curves (Figure 4).

229

In the joint meta-analysis, 12 (10.8%) novel variants were prostate tissue eQTLs, and 50

- 231 (45.0%) additional were eQTLs for other tissues. Two were missense substitutions (**Table S7**):
- rs1049742 in AOC1 and rs74543584 in MPZL2. Three additional novel variants had CADD
- scores>15: rs1978060, an eQTL for *TBX1* in prostate tissue; rs339331 an eQTL for *FAM162B* in adipose tissue; and rs57580158, an intergenic variant with evidence of conservation.
- 235

236 *Medication sensitivity analysis*

The UK Biobank (UKB) had medication information available to conduct a sensitivity analysis to see whether excluding individuals taking medications that could affect PSA levels (i.e., 5-alpha reductase inhibitors and testosterone) would impact our results. For PSA-associated variants, our primary results in the UK Biobank (UKB) were highly correlated (R=0.93, **Figure S3**) with the sensitivity analyses, suggesting these medications did not impact our results.

242

243 Out-of-sample PSA variance explained by PRSs

We evaluated different strategies for constructing PRSs for PSA levels first using results from our discovery cohort (see **Methods**). For testing these PRSs, four cohorts of men without PCa were out-of-sample: Kaiser Permanente's Genetic Epidemiology Research on Adult Health and Aging (GERA) cohort, the Selenium and Vitamin E Cancer Prevention Trial (SELECT),²³ the Prostate Cancer Prevention Trial (PCPT),²⁴ and All of Us (AOU)²⁵.

249

In GERA, PRS₃₁₈, constructed from the 318 conditionally-independent genome-wide significant variants in the multi-ancestry meta-analysis, generally had higher variance explained when using longitudinal measurements, rather than earliest PSA value, with 13.9% (95% CI=13.1%-14.6%) in European ancestry (n=35,322), 13.1% (95% CI=10.6%-15.6%) in Hispanics/Latinos (n=2,716), 9.3% (95% CI=6.8%-12.0%) in African ancestry (n=1,585), and 9.0% (95% CI=7.0%-11.4%) in East Asian ancestry (n=2,518). The variance explained in the other three cohorts was ~3-6% lower depending on the group (**Table S9**).

257

Expanding to a genome-wide approach, PRS-CSx (PRS_{CSx-disc}; included more than genomewide significant variants (1,070,230 SNPs; see **Methods**) and resulted in improved predictive
performance. The variance explained increased to 16.6% (95% CI=15.9%-17.5%) in men of
European ancestry and 18.2% (95% CI=15.4%-20.8%) in Hispanic/Latino men (**Figure 5A**, **Table S9**). The relative increase was largest in East Asian ancestry, with variance explained
reaching 15.3% (95% CI=12.7%-18.1%), and smallest in African ancestry, with variance
explained 8.5% (95% CI=6.1%-11.0%).

265

Second, we developed PRSs for PSA using the results from the joint GWAS meta-analysis (n=392,522), which combined the discovery meta-analysis with previously published results from Kachuri et al²⁰. These scores were validated in PCPT, SELECT, and AOU, but not GERA, which was included in the previously published meta-analysis and was therefore not out-ofsample.

272 For the independent genome-wide significant PRSs, PRS₃₁₈ explained 9.5% (8.8%-10.3%) of 273 variation in baseline PSA levels in SELECT European ancestry (n=22,173), while PRS₄₄₇ (from 274 the 447 conditionally independent genome-wide significant variants identified in the joint meta-275 analysis) explained 10.9% (10.2%-11.8%) of the variance, which exceeded the 8.5% (95% 276 CI=7.8%-9.2%) variance explained by PRS₁₂₈ (from the 128 independent variants described in 277 our prior GWAS of 95.768 men²⁰). Variance explained in PCPT European ancestry (n=5,725) 278 was slightly lower. In AOU European ancestry (n=11,922), variance explained was slightly 279 higher, with PRS₁₂₈ explaining 8.6% (95% CI=7.7%-9.6%), PRS₃₁₈ explaining 9.6% (95% 280 CI=8.6%-10.6%), and PRS₄₄₇ explaining 11.3% (95% CI 10.2%-12.4%). We did not observe an 281 appreciable change in differences across cohorts after removing individuals with BPH, a 282 condition known to influence PSA levels. However, variance explained was slightly higher in all 283 populations (<0.5% higher), albeit with overlapping CIs (Table S9). 284

- Among SELECT African ancestry (n=1,173), PRS₁₂₈ explained 3.4% (95% CI=1.6%-5.8%), PRS₃₁₈ explained 6.5% (95% CI=4.0%-9.5%), and PRS₄₄₇ explained 7.0% (95% CI=4.5%-10.1%); PRS₄₄₇ more than doubled variance explained by PRS₁₂₈. AOU African ancestry
- 288 (n=2,471) estimates were 1-2% smaller.
- 289

290 A genome-wide PRS-CSx (PRS_{CSx-ioint}) compared to PRS_{CSx-disc} modestly increased variance 291 explained by roughly 1-1.5% in European ancestry in PCPT (11.6%, 95% CI=10.0%-13.1%), 292 SELECT (13.9%, 95% CI=13.1%-14.9%), and AOU (14.7%, 95% CI=13.5%-16.0%). PRS_{CSx-ioint} 293 also improved ~3% upon the previously published PRS from the Kachuri et al.²⁰ paper 294 estimated here to be 8.6% in PCPT and 10.4% in SELECT for PRS-CSx (PRS_{CSx-Kachuri}, Table 295 **S9**). Among men of African ancestry in SELECT, PRS_{CSx-joint} showed no improvement (7.2%, 296 95% CI=4.6%-10.0%) over PRS_{CSx-disc}, while variance explained in AOU increased by 0.3% 297 (5.8%, 95% CI=4.1%-7.8%). Notably, PRS_{CSx-ioint} yielded a substantial improvement upon the previously published PRS_{CSx-Kachuri} estimates²⁰ of 1.64% in SELECT, although still under half of 298 299 that in European ancestry.

300

In SELECT European ancestry individuals, PRS-CSx explained 13.9% of variation, while PRS₄₄₇
 explained 10.9% of the variation. Assuming that variation explained is nested between these
 approaches, we estimate 78.4% (=10.9%/13.9%) of PRS-CSx variation may be explained by
 PRS₄₄₇. This is expected since information across the different PRSs overlaps, and the initial
 genome-wide significant SNPs from our large-scale GWAS are the most informative for
 explaining variation in PSA levels.

- 307
- 308 Third, we examined how the variance in PSA levels explained by the PRSs varied by age.
- 309 These analyses were performed in GERA to have a large enough sample size in each age
- 310 group and used PRS_{CSx-disc} to provide out-of-sample estimates. The estimated variance
- 311 explained by the PRSs decreased with increasing age in all GERA ancestry groups, albeit with
- 312 somewhat wide confidence intervals (Figure 5B, Table S10). For example, PRS_{CSx-disc}
- 313 explained 16.4% (95% CI 14.6%-18.5%) of variation in PSA levels among European ancestry
- 314 individuals <50y, and this decreased to 8.7% (95% CI 7.0%-10.5%) for men ≥80y.

315

- 316 Finally, for PRSs constructed from genome-wide significant independent variants, the variance
- 317 explained when using weights corresponding to effect sizes from the multi-ancestry meta-
- 318 analysis was almost always equal to or higher than variance explained when using ancestry-
- 319 specific weights (Table S10). This was observed both for the discovery (PRS₃₁₈) and joint meta-
- 320 analysis (PRS₄₄₇). The few instances where the variance explained was estimated lower almost
- 321 always had <1% difference and wide confidence intervals around the estimate (i.e., the smallest
- 322 sample sizes likely had unstable estimates).
- 323

324 *Relationship of PSA PRSs with PCa aggressiveness using Gleason score*

- 325 In GERA, we performed a case-only analysis to examine the association between PSA
- $\label{eq:product} 326 \qquad \mathsf{PRS}_{\mathsf{CSx},\mathsf{disc}} \text{ (the out-of-sample PRSs with the highest variance explained) and Gleason score.}$
- 327 Results were consistent with previous work that suggested that screening bias decreases the
- 328 likelihood of identifying high-grade disease, whereby men with higher PRS values (indicating a
- 329 genetic predisposition to higher constitutive PSA levels) are more likely to be biopsied, but less 330 likely to have high grade disease²⁰; we found that in European ancestry cases, an SD increase
- in PRS_{CSx-disc} was inversely associated with Gleason 7 (OR=0.78, 95% CI=0.73-0.84, p=1.2e-
- 332 13) and ≥8 (OR=0.71, 95% CI=0.64-0.79, p=6.2e-10) compared to Gleason ≤6. Other ancestry
- 333 groups had similar estimated ORs, though they were not always statistically significant, likely
- owing to sample size (Table S11; e.g., African ancestry Gleason 7 (OR=0.88, 95% CI=0.67-
- 335 1.17, p=0.39) and ≥8 (OR=0.65, 95% CI=0.43-0.99, p=0.043)).
- 336

337 Impact of genetically-adjusted PSA on prostate biopsy eligibility

- We examined how PRS_{CSx,disc} would have changed biopsy recommendations for cases and controls, according to age-specific thresholds in GERA (see **Methods**). In European ancestry individuals who had negative biopsies (i.e., controls, n=2378), 16.0% with unadjusted PSA levels that exceeded age-specific thresholds for biopsy were reclassified to ineligible for biopsy. Among controls with PSA levels that did not indicate biopsy, 2.4% were reclassified to biopsy eligible, resulting in a control net reclassification improvement (NRI) of 13.6% (95% CI=12.2%-
- 15.0%; **Figure 6A**, **Table S12**). In individuals with positive biopsies (i.e., cases; n=2,358), 3.9%
- 345 were reclassified to eligible, while 13.1% were reclassified to ineligible, resulting in a case NRI
- of -9.2% (95% CI=-10.3% to -8.0%). Of cases who became ineligible, 71.1% had Gleason
- scores ≤7, as compared to 56.5% who remained eligible (although we note that some of these
- 348 men may have had biopsies for reasons other than their PSA level, such as abnormal digital
- 349 rectal exam or strong family history). In African ancestry controls (n=110), 16.0% were
- reclassified to ineligible, while 2.4% were reclassified to eligible, resulting in an NRI of 3.6%
- 351 (95% CI=0.1% to 7.1%; **Figure 6B**). In African ancestry cases (n=310), 5.2% were reclassified
- to eligible and 6.8% were reclassified to ineligible, resulting in an NRI of -1.6% (95% CI=3.0% to
- -0.2%). Other groups are shown in **Figure S4** with details in **Table S12**. We additionally
- obtained eight years of additional follow up on the 78 controls in all groups now classified as
- 355 eligible; three were later diagnosed with PCa.

356

357 To assess potential variability in genetic adjustment across PSA levels, we compared measured 358 versus genetically adjusted PSA levels across a range of values in GERA men. Plotting 359 measured versus adjusted PSA indicated consistent relative adjustment on the log scale (Figure S5). For example, at a measured PSA of 2.5, 6.5, and 10.0 ng/ml, the genetically 360 361 adjusted PSA' IQR ranged from 2.6-3.7, 4.6-6.8, and 9.1-12.5, respectively. These results 362 suggest genetic adjustment is applicable to PSA values <20 displayed in the figure, although 363 the implications are most profound around values where clinical decisions are made (e.g., near 364 age-specific PSA thresholds).

365

366 Impact of genetically-adjusted PSA on overall and aggressive PCa

Previous work has suggested that midlife PSA predicts lethal PCa²⁶. In GERA European 367 368 ancestry, genetically-adjusted midlife log PSA had a larger estimated magnitude of association 369 with overall PCa (OR=4.57, 95% CI=4.27-4.88) than measured PSA (OR=4.30, 95% CI=4.04-370 4.58)), though the CIs overlapped. The difference between associations was even larger for 371 aggressive disease, with OR=3.92 (95% CI=3.54-4.35) for adjusted vs. OR=3.46 (95% CI=3.15-372 3.81) for measured, though again CIs overlapped. African ancestry showed similar trends, with 373 the genetically-adjusted association with PCa OR=5.85 (95% CI=4.73-7.23) vs. measured 374 OR=4.72 (95% CI=3.56-6.27), and the aggressive genetically-adjusted OR=5.39 (95% CI=3.95-375 7.35) vs. measured OR=4.72 (3.56-6.27). Estimates in Hispanic/Latino were also similar, but 376 East Asian ancestry showed no difference (Table S13). Cross-validated AUC estimates also 377 showed essentially no difference between adjusted and measured PSA, with estimates ranging 378 from 0.7-0.8 in the different groups (Table S13).

379

380 Associations with previously-reported PCa variants

381 In our discovery cohort, 20 of our 184 novel PSA-associated variants (10.8%) were genomewide significantly associated with PCa in the PRACTICAL consortium's European ancestry 382 383 GWAS²⁷ (Tables S4, S6). An additional 19 variants (10.3%) were associated with PCa at a 384 Bonferroni level (p<0.05/184=0.00027). With correction for bias related to more frequent screening in men with higher constitutive PSA levels (see Methods)^{20,28}, this count was reduced 385 to 13 (7.0%) significant at the genome-wide level, and an additional 14 (7.6%) at the Bonferroni-386 387 corrected level. Out of the 111 novel PSA-associated variants from the meta-analysis, 8 (7.1%) 388 were genome-wide significantly associated with PCa, and an additional 11 (9.8%) were 389 significant at a Bonferroni level (p<0.00045). With bias correction, 5 (4.5%) were genome-wide 390 significant, and an additional 4 (3.6%) were Bonferroni-significant.

391

392 Associations with previously reported BPH variants

In our discovery cohort, one variant (rs1379553) was genome-wide significantly associated with BPH out of 137 variants available in a GWAS in UKB European ancestry²⁹. An additional eight met a Bonferroni level (p<0.05/137=0.00036). Out of the 96 available variants identified from the meta-analysis, one variant was genome-wide significant (rs627320), and 6 more met a Bonferroni level (p<0.045/96=0.00052).

399 Associations with urinary symptom variants

- 400 In variants identified in our discovery cohort, rs12573077 (p=8.4e-5) met a Bonferroni level
- 401 (p<0.05/177=0.00028) for a test for an association with urinary symptoms in the GERA cohort
- 402 (Table S4, S6, S14). In variants identified in the joint meta-analysis, none met a Bonferroni level
- 403 of significance (p<0.05/110=0.00045).
- 404

405 **PSA variant associations with prostate volume**

We found that 31 of the 407 PSA variants tested demonstrated some evidence of an
association with prostate volume in the PASS cohort. rs182464120 on chromosome 19 was
strongly associated (p=2.0e-11), rs12344353 on chromosome 9 was associated at a Bonferroni
level (p=5.3e-5 <0.05/407=0.00012), and 29 other variants were associated at a nominal
significance level (p<0.05) (Table S15).

411

412 Associations with KLK3 plasma pQTL

413 We annotated the 447 variants from the joint GWAS meta-analysis using recently published

- 414 plasma pQTL association results for *KLK3* from the UKB Pharma Proteomics Project using the
- 415 Olink Explore platform;³⁰ 409 had corresponding pQTL associations in the UKB. In European
- ancestry individuals (n=46,214), GWAS and KLK3 pQTL effects were highly correlated (R=0.85,
- 417 p=3.7e-117) (**Figure S6**). Eleven variants were associated with relative *KLK3* abundance at
- 418 p<0.05/409, and, as expected, the strongest two associations were in *KLK3* (rs17632542,
- rs61752561) (**Table S16**). Among African ancestry individuals (n=1,065), we observed an
- 420 attenuated correlation with effects on *KLK3* abundance (R=0.14, p=0.0034), although none of
- 421 the individual pQTL associations reached statistical significance.
- 422

423 Associations with eGenes

- In our sc-RNA-seq data analysis, we found that each of the eGenes for PSA-associated variants
- is expressed across prostate cells. This is especially true in prostate luminal epithelial cells
- 426 (which produce PSA) and is expected if the genes modify PSA levels (**Table S17**). **Figure S7**
- 427 shows expression of the eQTL genes across multiple prostate tissue cell types, including luminal
- 428 cells of the prostate epithelium and its precursor cells (e.g., basal epithelial cells of prostate;
- 429 expression sorted by *KLK3*). Percentile expression of the eQTL-associated genes was significantly
- higher in luminal cells than all other prostate cell types (P=0.0006), suggesting these genes are
- 431 more active in this cell type than other prostate cells (**Figure S8**) and supporting the hypothesis
- that these eQTL genes are involved in PSA expression.

434 **Discussion**

- 435 Our GWAS detected 448 genome-wide significant variants associated with PSA levels, of which 436 295 were novel (184 in discovery and 111 in a meta-analysis), nearly quadrupling the total
- 437 number of associated variants. The variance explained by genome-wide PRSs ranged from
- 438 11.6%-16.9% in men of European ancestry, 5.5%-9.5% in men of African ancestry, 13.5%-
- 439 18.6% in Hispanics/Latinos, and 8.6%-15.3% in the East Asian ancestry group. We also
- observed a decline in PRS predictive performance with increasing age, particularly at the oldest
- 441 ages. The majority of newly identified variants were uniquely associated with PSA and not PCa.
- 442

443 Our discovery cohort included more African ancestry individuals than any prior study of PSA 444 genetics. Of the eight genome-wide significant variants that were identified in the discovery 445 phase in African ancestry, only two were sufficiently common to be assessed in European 446 ancestry. Of those two, the association between rs1203888 (LINC00261) and PSA levels was 447 unique to the African ancestry population. These eight variants generally failed to meet 448 Bonferroni significance in our replication cohort, although the sample size was small (3.509 449 individuals of African ancestry); the variant rs18447639 in the AR gene was closest to 450 replicating. Androgen receptor (AR) signaling is required for normal prostate development and function but is hijacked during carcinogenesis.³¹ Because prostate tumor growth and 451 progression depend on AR signaling, androgen deprivation therapy remains a frontline 452 453 treatment for progressing PCa, and the inhibition of AR activity may delay progression.³² 454

455 A total of 10.8% of novel discovery and replication variants were prostate tissue eQTLs, and 456 another 49.7% were eQTLs in other tissues. In addition, 16 discovery variants and five meta-457 analysis variants had predicted deleterious regulatory effects. Putative deleterious genes 458 included: AOC1, which regulates histamine metabolism and sensitivity to non-steroidal anti-459 inflammatory drugs^{33,34}; *MPZL2*, which is involved in thymus development and T-cell maturation; 460 and ZC3HC1, a regulator of cell cycle progression and established susceptibility locus for 461 coronary artery disease^{35,36}. We also observed an association with PSA levels for the deltaF508 462 mutation in CFTR that causes cystic fibrosis, which is accompanied by infertility in 97% of 463 affected males³⁷ and has been linked to obstructive azoospermia (ClinVar³⁸ accession 464 SCV001860325). We detected another signal with possible links to male fertility, rs372203682 465 in LMTK2, a gene implicated in spermatogenesis³⁹ that interacts with AR and inhibits its 466 transcriptional activity⁴⁰.

467

In SELECT, the variance in PSA levels explained by our independently associated GWAS variants was ~1% larger than previously explained²⁰ in European and ~3% higher in African ancestry individuals. The variance explained in SELECT and PCPT was substantially less than that in GERA, even though we evaluated only variants from our discovery cohort (which did not

472 include GERA). This may be due in part to the studies' selection criteria, as individuals in

473 SELECT and PCPT were required to have PSA \leq 3 ng/mL²³ and \leq 4 ng/mL²⁴, respectively, at

baseline. However, in AOU, which did not have this selection criteria, variance explained for
European ancestry men was at most 0.5% higher than SELECT, and thus also lower than

476 GERA. For African ancestry men in AOU, variance explained was 2-3% lower than in SELECT,

suggesting that differences in performance may be attributed to factors other than preferential
selection for low baseline PSA. We also investigated whether BPH may contribute to variability

in PRSs performance. The estimated variance explained was <0.5% higher when excluding

480 men with a BPH diagnosis. By BPH, we mean a clinical diagnosis rather than presence of BPH.

481 Most patients evaluated for potential PCa have evidence of BPH, which can result in elevated

482 PSA levels^{41,42}. These findings highlight the need to evaluate genetically adjusted PSA in a

483 wider range of clinical settings, as well as the challenges with curating out-of-sample cohorts

484 with clinical data sufficient for such evaluations.

486 The performance of PRS constructed using weights derived from the multi-ancestry meta-487 analysis typically matched or surpassed the performance of PRSs based on ancestry-specific 488 weights. As expected, genome-wide PRS-CSx generally achieved 1-6% higher explained 489 variance than the PRSs limited to mJAM genome-wide significant variants. However, the 490 improvement in performance observed for PRS-CSx was not equal across populations. The 491 largest increase was observed for Hispanic/Latino men, followed by European ancestry men 492 (generally similar to Hispanic/Latino men), followed by Asian ancestry men. To our knowledge, 493 this is the first time out of sample PRS performance was assessed in a Hispanic/Latino 494 population. Relative to the fine-mapped PRS, the degree of improvement was smallest for 495 African ancestry. This may be due to a number of factors. First, PRS-CSx uses a single 496 hyperparameter to couple posterior effect sizes across ancestry groups, which may be 497 insufficient to capture different correlation structures among populations. Second, HapMap3 498 variants used by PRS-CSx do not tag genetic variation equally well across ancestries. Fine-499 mapping PRS methods do not limit to this set of tagging SNPs and may be more likely to 500 capture population-specific variants. Third, the choice of linkage disequilibrium (LD) reference 501 panels has slightly different implications for the two PRS approaches. PRS-CSx relies on LD 502 reference panels for estimating joint SNP effect sizes, while fine-mapping requires LD 503 information for identifying independent variants from summary statistics. mJAM advances other 504 fine-mapping approaches by incorporating population-specific LD, which is more accurate than using a single population as the LD reference²¹ or only making use of the largest ancestry 505 506 group. While PRS-CSx provides more flexibility to accommodate different genetic architectures, 507 it may be more sensitive to the choice of LD reference panels and mismatches in LD structure 508 between PRS training and testing populations, especially without a separate dataset for 509 parameter tuning.

510

511 We found that genetically adjusting PSA levels reduced unnecessary biopsies in controls, albeit 512 less so than in previous work²⁰ in the same GERA population. It is likely that our previous study 513 overestimated reclassification in controls because there was partial overlap between the GWAS 514 meta-analysis used to train the PRS used for adjustment - GERA was included - and the 515 population in which we undertook genetic adjustment. In the present study, we performed 516 genetic adjustment using a PRS trained on a large GWAS that did not include GERA. We also 517 saw an increase in magnitude in genetically-adjusted midlife PSA association with PCa in most GERA groups, although CIs overlapped for all, and while our previous study²⁰ did not see any 518 519 benefit in African ancestry, here we saw an increase.

520

521 Our investigation had several limitations. Relative to prior studies of PSA genetics, the discovery 522 and replication cohorts included here substantially increased the number of men from diverse 523 populations. While both were very large (N~300K and ~100K men total), the replication cohorts 524 had disproportionately smaller African ancestry (discovery N ~58K and replication N ~3.5K) and 525 Hispanic/Latino populations (N~24K and ~3K). Going forward, our PSA Consortium will continue 526 to seek new study populations with both genotypic and phenotypic data that represent diverse 527 participants. Nevertheless, for African ancestry, 43% of variants met a nominal replication 528 threshold, many more than the 5% that would be expected by chance. We also suspect that we

529 had limited power to detect effect size heterogeneity, especially since variants that exhibited 530 significant heterogeneity were mostly known variants in strongly associated regions. Another 531 limitation is that GERA biopsy reclassification may have been specific to Kaiser Permanente 532 clinical guidelines, as previously discussed²⁰. In addition, while we did our best to restrict 533 relevant analyses to PCa-free individuals, some individuals likely had undetected PCa⁴³. 534 However, the number was unlikely to be large enough to materially impact our results because 535 our study population was relatively young; the average age among men in the MVP (which 536 comprised a large majority of our discovery study population, N~286K) was 58 years for men of 537 European ancestry, 52 years for men of African ancestry, and 54 years for Hispanic/Latino men 538 or Asian ancestry men. Further, the PSA PRS_{CSx} explained increasing variability in PSA levels 539 for individuals of younger ages. Most novel PSA-associated variants were not associated with 540 PCa, and those that were may have been due to screening bias, as previously shown²⁰. The 541 lack of BPH information in most of our cohorts was an additional limitation, but most novel 542 variants associated with PSA levels were not associated with BPH in others' work on UKB 543 European ancestry individuals²⁹, and the variance explained by PRSs in SELECT was affected 544 by <0.5% in participants with BPH. We were unable to account for prostate volume, a strong 545 predictor of PSA levels⁴⁴. Finally, we note that our GWAS and resulting PRSs were developed 546 for total PSA. Future work should work toward capturing genetic factors that are specific to 547 constituents of total PSA.

548

549 In summary, we undertook a large-scale, multi-ancestry study with over three times the sample size of previous work,²⁰ expanded our understanding of the genetic basis of PSA levels and our 550 551 potential to improve the accuracy of PSA genetic adjustment across ancestries. Using an 552 ancestrally diverse study population, we detected hundreds of novel variants associated with 553 PSA levels that were largely independent of PCa and BPH. These findings explain additional 554 variation in PSA levels, especially among men of African ancestry, who suffer the highest 555 morbidity and mortality due to PCa, as well as among Hispanic/Latino men. This highlights the 556 importance of studying diverse populations to enable novel discoveries and construct PRS that 557 will perform equally across ancestry groups. Taken together, our work moved us closer to leveraging genetic information to personalize and substantially improved our understanding of 558 559 the genetic basis of PSA levels and of genetic adjustment of PSA levels across individuals of 560 diverse ancestries.

561

562 Methods

563 **Discovery participants and phenotype measurements**

564 Our primary analyses included 296,754 men from seven cohorts that had not previously been 565 analyzed in studies of PSA genetics. These are described briefly below; additional details, 566 including array, ancestry, imputation reference panels, sample sizes, number of variants, and 567 standard filters applied are described in **Tables S1-S3**. To ensure participants had a functional 568 prostate unaffected by surgery or radiation and to exclude individuals at a high risk of 569 undiagnosed PCa⁴⁵, participants were restricted to men with no history of PCa or surgical resections of the prostate, and at least one PSA measurement between 0.01 and 10ng/mL. 570 571 Analyses were based on each individual's earliest recorded PSA level. For descriptive statistics,

572 meta-analysis of PSA medians from each cohort was done with the weighted median of medians method in the R v4.2.3⁴⁶ package metamediation v1.0.0⁴⁷. Sub-populations were 573 574 defined by self-identified race/ethnicity and/or genetically-inferred ancestry, depending on the 575 cohort. 576 577 African American Prostate Consortium (AAPC). The AAPC is comprised of African ancestry 578 studies with PCa phenotyping.²⁷ 579 580 Mount Sinai BioMe® Biobank (BioMe). BioMe is a longitudinal cohort linked to Epic electronic health records (EHRs)⁴⁸. Individuals were European ancestry, Hispanic/Latino, and African 581 582 ancestry. 583 584 Chicago Multiethnic Prevention and Surveillance Study (COMPASS). COMPASS is a 585 longitudinal study of Chicagoans with >11,000 participants currently enrolled (82% African 586 American).⁴⁹ PSA data has been described previously⁵⁰. 587 588 Men of African Descent and Carcinoma of the Prostate (MADCaP). MADCaP is a consortium of 589 epidemiologic studies addressing the high PCa burden in African ancestry men.^{51,52} 590 591 Multiethnic Cohort (MEC). MEC is a prospective cohort study that enrolled >215,000 Hawaii/Los 592 Angeles residents ages 45-75 years between 1993-1996.^{53,54} 593 594 Million Veteran Program (MVP). MVP is a multi-ancestry cohort recruited nationwide. 595 Information is obtained from EHRs, including inpatient International Classification of Diseases 596 (ICD)-9 codes, Current Procedural Terminology (CPT) procedure codes, clinical laboratory 597 measurements, and reports of diagnostic imaging modalities⁵⁵. Sub-populations were created using the harmonized ancestry and race/ethnicity (HARE) method.⁵⁶ 598

599

603

Southern Community Cohort Study (SCCS). SCCS is a prospective cohort study that recruited
 85,000 predominantly African ancestry adults from community health centers in the
 southeastern United States. This study included only men of African ancestry.⁵⁷

604 **Replication cohorts**

605 Genome-wide significant variants identified in the discovery cohort were tested for replication in 606 the previous largest GWAS of PSA levels, which included 95,768 men (85,824 European 607 ancestry, 89.6%)²⁰, using a Bonferroni corrected α level. In addition, previously-identified 608 genome-wide significant variants ²⁰ were tested for replication in our independent discovery 609 cohort. Statistical tests throughout were two-sided.

610

611 Additional PRS evaluation cohorts

For our discovery cohort results, we evaluated PSA PRS performance and reclassification in

613 individuals from the GERA cohort (also in the replication cohort, out-of-sample for the discovery

- 614 cohort (n=35,322; 28,503 European; 2,716 Latino; 2,518 East Asian; and 1,585 African
- 615 American)).
- 616
- 617 Additional out-of-sample cohorts for (both the discovery analysis and the joint meta-analysis of
- 618 discovery and replication) PRS assessment was done in genotyped individuals from the PCPT²⁴
- 619 (n=5,725 European) and SELECT²³ (n=25,366; 22,173 European; 1,763 African
- 620 American/European; 1,173 African American; and 257 East Asian) and All of Us (AOU;
- 621 n=17,512; 11,922 European; 2,469 African American; 1,783 other; 1,336 Hispanic/Latino)²⁵,
- 622 which have been previously described. Briefly, PCPT and SELECT began as randomized,
- 623 placebo-controlled, double-blind clinical trials of finasteride and selenium and vitamin E,
- respectively, and both enrolled men ≥55y. Individuals in SELECT and PCPT were required to
- have PSA \leq 3 ng/mL²³ and \leq 4 ng/mL²⁴, respectively, at baseline. The National Institutes of Health
- 626 (NIH) AOU cohort is committed to including groups that have been historically underrepresented
- 627 in research²⁵. From AOU, we selected individuals with PSA>0.01 between the ages of 40 and
- 628 90, with short-read whole-genome sequencing (WGS) data and no survey or EHR
- 629 conditions/observations reflecting a history of PCa. The median PSA measurement we used
- 630 was required to be ≤10 ng/mL. PRSs were calculated with the WGS data subset to variants with
- 631 population-specific allele frequency ≥1% or a population-specific allele count >100 for any
- 632 genetic ancestry. Genetic ancestry was determined using a random forest classifier trained on
- the principal component (PC) space of the Human Genome Diversity Project and 1000
- 634 Genomes Project (KGP)⁵⁸.
- 635

636 Ethical considerations

- Informed consent was obtained from all study participants. AAPC was approved by their IRB.
 The ethics review board of the Program for the Protection of Human Subjects of Mount Sinai
- 639 School of Medicine approved BioMe (#HSD09-00030, #07-0529 0001 02 ME). The University of
- 640 Chicago Biological Sciences Division IRB Committee A (#IRB12-1660) approved COMPASS.
 641 Local and national IRBs approved MadCAP. MEC was approved by their IRB. The VA Central
- 642 institutional review board (IRB) approved the MVP. The IRBs at Vanderbilt University and
- 643 Meharry Medical College approved SCCS. Vanderbilt University Medical Center IRB approved
- 644 BioVU. GERA was approved by the Kaiser Permanente Northern California IRB and the
- 645 University of California, San Francisco. A local ethics committee approved the Malmo Diet and
- 646 Cancer Study (MDCS). The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening
- 647 Trial was approved by the IRBs at each participating center and the National Cancer Institute,
- and the informed consent document allows data use for cancer and other adult disease
- 649 investigations; we used publicly posted summary statistics, for which no IRB is required. The
- research was conducted with approved access to UKB data (#14105).
- 651

652 Genotype quality control and imputation

- 653 Study subjects were genotyped using conventional GWAS arrays (Table S1). Genotypes were
- then imputed using imputation servers⁵⁹, Minimac3⁶⁰, or IMPUTE2⁶¹. The vast majority of
- 655 studies imputed to the KGP phase 3 reference panel⁶², with one sub-study imputing to KGP
- 656 phase 1 just for the X chromosome⁶³ and another imputing to the TOPMed reference panel⁵⁹.
- 657 Since all but two studies (>95% of participants) used genome build 37, welifted over the
- assembly of those from build 38 using triple-liftOver⁶⁴ v133 (2022-05-20), an extension of
- 659 LiftOver⁶⁵ that accounts for regions that are inverted between builds.
- 660
- 661 Standard genotype and individual-level QC procedures were implemented in each ancestry
- group in each participating study. Specific study protocols are delineated in **Table S1**, with
- additional QC steps and details in **Table S2**. Unless information was unavailable or a filter did
- not make sense for a particular group, variants were retained if their imputation quality score
- 665 was ≥0.3, their MAF was ≥0.5% if the sample size was ≥1000 and ≥5% otherwise, their Hardy-
- 666 Weinberg equilibrium (HWE) was ≥1e-8, they were mapped in build 37, and they had an MAF
- difference ≤0.2 compared to KGP populations (full details in **Table S3**). For the cohorts that
- 668 meta-analyzed sub-cohorts (e.g., the three small African ancestry sub-cohorts within the SCCS
- 669 African ancestry group; **Table S2**), we also required that variants be present in all sub-cohorts
- 670 (necessary for multi-ancestry analysis method limitations, although this removed only a very
- small number of variants, **Table S3**). Finally, we excluded variants if they were present in only
- 672 one study with n < 2,000.
- 673

674 Association analyses

- 675 GWAS within each ancestry group in each study were undertaken using linear regression of log 676 PSA on additive genotypes, and, when using multiple measurements, the long-term average 677 residual by individual⁶⁶. The minimum set of covariates included age at PSA measurement and 678 genetic ancestry PCs. If available, GWAS also adjusted for batch/array, body mass index, and 679 smoking status (Table S1). Meta-analyses of each ancestry group and across the overall 680 discovery cohort were conducted using inverse-variance weighted fixed effects models using a 681 custom patched version of METAL v2011-03-25 that prevents numerical precision loss (lines 682 633 and 635 of "Main.cpp" modified to the number 15 to output 15 digits precision)⁶⁷. We also 683 assessed heterogeneity with Cochran's Q across the four ancestry groups.
- 684
- 685 To identify independently associated genome-wide significant (p≤5e-8) variants with
- 686 computational efficiency, we first formed clumps of genome-wide significant variants such that
- 687 all clumps were ≥10Mb apart and independent of one another; specifically, the top variant was
- 688 chosen, genome-wide significant variants ≤10Mb from any variant in the clump were added to
- the clump, the process was iterated until a final clump was formed, and then the process was
- 690 repeated to form more clumps (i.e., clumps were created such that there was no additional

- 691 genome-wide significant variant \leq 10Mb). Within each clump, we used mJAM v2022-08-05²¹,
- 692 which uses population-specific LD reference panels for each contributing cohort and ancestry
- 693 group to model the correlation among variants, with an $r^2 < 0.01$ threshold in all ancestry groups.
- 694 Genotypes utilizing the appropriate GERA cohort group (European, Hispanic/Latino, African
- 695 American, and East Asian) served as references⁶⁸.
- 696
- 697 To maximize discovery efforts, we combined our discovery cohort (n=296,754) with our 698 replication cohort (n=95,768), for a total of 392,522 individuals.
- 699
- Associations were considered novel if they had low LD from all previously-reported variants²⁰.
- 701 Specifically, we required $r^2 < 0.01$ in all four ancestry groups, again using GERA as LD reference.
- 702

703 Annotation

- 704 Variants were annotated using FUMA⁶⁹. We first prioritized genes that included a significant
- 705 prostate eQTL from GTeX v8 (www.gtexportal.org). We then prioritized other significant eQTLs
- and finally by closest gene. Deleteriousness of mutations was determined by CADD scores; a
- recommended cutoff to identify potentially pathogenic variants of scores ≥15 has been
- suggested (the median of splice site changes and non-synonymous variants from CADD v1.0;
- corresponds to the top 3.2% of variants)⁷⁰. Gene functions were characterized with RefSeq⁷¹.
- 710 Circos plots were generated using Circos v0.69-6⁷².
- 711

712 *Medication sensitivity analysis*

- 713 Some of our study participants may have taken medications that can affect PSA levels. In
- particular, 5-alpha reductase inhibitors and testosterone can impact PSA levels^{73,74}. We
- assessed the use of these medications among 26,669 men of European ancestry in the UKB
- 716 with at least one PSA measurement. Men with a prescription for at least one of the two
- 717 medications prior to PSA measurement were considered users. Ten percent of the men were
- prescribed 5-alpha reductase inhibitors and 0.56% testosterone. We also controlled for potential
 confounding by alpha blocker use.
- 720

721 Out-of-sample PRS variance explained

- We calculated PRSs to assess the overall PSA variance explained by genetics, and to adjust PSA measurements for PSA genetics. All PRS results are shown only in independent cohorts (i.e., training dataset completely independent of testing dataset), such that assessments of performance are unbiased. Nonparametric bootstrap percentile CIs for variance explained were calculated using 1000 replicates.
- 727
- We used two sets of individuals to construct the PRSs. First, we constructed PRSs from our
- discovery cohorts to allow assessment in GERA, PCPT, SELECT, and AoU. Second, we
- 730 constructed PRSs from the meta-analysis of discovery and replication cohorts (which included
- 731 GERA), with assessment in PCPT, SELECT, and AoU only. For GERA we included results

using first and multiple measurements; for PCPT and SELECT we include results using the firstmeasurement.

734

735 We also used two sets of variants to calculate the PRSs in each of the two sets of individuals.

- 736 We first utilized the independent genome-wide significant variants discovered in our analyses
- 737 (one for discovery and one for the meta-analysis of discovery and replication). Second, we
- constructed a genome-wide score using PRS-CSx v2023-08-10⁷⁵, which was implemented
- vilizing GWAS summary statistics, the 1,287,078 HapMap3 variants as an LD reference that
- had an imputation quality >0.9 in SELECT, using a global shrinkage parameter of ϕ =0.0001
- (which performed well in our previous work²⁰), and variants with imputation quality \geq 0.9. Since
- 742 PRS-CSx only considers autosomes, independent genome-wide significant X chromosome
- variants were included (and produced a negligible increase in performance). The final scores
- were calculated by summing the effect size times the (probabilistic) number of alleles at each
 locus with PLINK v2.00a3.7LM⁷⁶.
- 746

747 We also assessed the variance explained by the discovery PRS-CSx within age intervals in

GERA; we looked only in GERA to have an out-of-sample estimate from discovery and a large
enough sample size at each age. An individual could be in multiple bins, but using just the first
measurement of that individual per age bin.

751

752 Fur PSA for PCa screening in GERA

We adjusted PSA levels as has been described previously²⁰. Briefly, PSA values for individual i were adjusted by PSA_i^{adj} = PSA_i / a_i , where a_i is a personalized adjustment factor derived from our PRS, as: $a_i = \exp(PRS_i)$ / $\exp(mean(PRS))$. Here we estimated the mean(PRS) value within each group in the GERA cohort. We then evaluated the potential utility to alter biopsy referrals using age-specific PSA thresholds used within the Kaiser system (40-49y=2.5, 50-59y=3.5, 60-69=4.5, and 70-79=6.5 ng/ml⁷⁷), evaluating net reclassification in cases and controls²⁰.

- 759
- 760 We also tested for associations of our PSA^{adj} with Gleason score ($\leq 6, 7, and \geq 8$) using
- 761 multinomial logistic regression with the R package nnet v7.3.18⁷⁸.
- 762

To assess whether there was variability in PSA adjustment across PSA levels, we first binned PSA values (with smaller ranges in lower values where there was more data). Within each bin, we computed PSA - PSA_{adjusted}, and then computed the median and IQR of these values. The median and IQR were then plotted at the center point of each bin by adding them to the identity line.

- 768
- 769 Impact of genetically-adjusted midlife PSA on overall and aggressive PCa prediction
- 770 We next investigated the impact of genetically adjusting PSA on the prediction of overall and
- aggressive PCa in the GERA cohort (3540 cases [1,028 aggressive, Gleason ≥7], 21,702

- controls). We constructed a midlife PSA²⁶ based on each participant's median PSA between 50-
- 773 60y, with cases restricted to measurements ≥1y before diagnosis. Genetic PSA adjustment was
- performed as in the previous section. Associations between PSA or genetically adjusted log
- PSA and PCa risk were assessed using logistic regression for overall PCa cases vs controls
- and for aggressive cases vs. controls, adjusting for covariates in Table S1. AUC was estimated
- using 10-fold repeated cross-validation (10 repeats) with caret v6.0.90⁷⁹.
- 778

779 Bias-corrected PCa estimates

- PCa associations in individuals with European ancestry in the PRACTICAL consortium²⁷ were
- adjusted for screening bias²⁸, using estimates previously derived²⁰: $\beta'_{Cancer} = \beta_{Cancer} b\beta_{PSA}$,
- 782 SE'_{Cancer}=(SE_{Cancer}² + b²SE_{PSA}² + SE_b² β_{PSA} + SE_b²SE_{PSA}²), where SE is the standard error, and
- restimates were b=1.144, and SE_b=2.909e-4.
- 784

785 Associations with urinary symptom variants

- We evaluated whether the novel PSA variants were associated with urinary symptoms in the
 GERA cohort. Individuals in this cohort completed the first 6 (of 7) questions from the American
- 788 Urological Association Symptom Index (AUA-SI)⁸⁰ with 5-point Likert scale responses. The
- 789 questions asked about incomplete emptying, frequency, intermittency, urgency, weak stream,
- and straining (Table S13). The one missing question from the AUA-SI regarded nocturia. We
- calculated total scores as the sum of the questions, giving each individual a value ranging from
- 792 6-30. The score was dichotomized at <7, ≥7 to differentiate men with little or no BPH
- 793 (N=12,846) from those with moderate or severe BPH (N=15,480). We then assessed the
- association between the PSA variants and the urinary symptom score.
- 795

796 Prostate volume analysis

We evaluated associations between PSA variants and prostate volume in patients on active 797 798 surveillance (AS) enrolled in the Canary Prostate Active Surveillance Study (PASS). Between 799 2008-2017, PASS prospectively enrolled 1455 patients with clinically localized PCa (cT1-cT2 and Gleason Grade 1-2) to undergo AS at one of 10 national sites⁸¹. Prostate volume was 800 801 measured at diagnosis, with a median measurement of 43.0cc (IQR=31.0-57.5). The median 802 age at diagnosis was 63 years (IQR=58-67), and 85% of the PASS cohort self-reported as European ancestry. Genotyping was conducted in 1,220 participants⁸². We assessed potential 803 804 associations between the 407 PSA variants that we successfully imputed in PASS and prostate 805 volume using mixed models with fixed effects for genetic variants, age at diagnosis, and 10 806 PCs, and a random effect for a genetic relationship matrix.

- 807
- 808 Associations with eGenes

- 809 We used single cell RNA sequencing (scRNA-seq) data to assess whether the eGenes for PSA-
- 810 associated variants (Table S7) are expressed in secretory prostate cell types, particularly
- 811 luminal epithelial cells, more so than other prostate cell types. For these analyses, we used data
- 812 from the Chan Zuckerberg Cell by Gene census v2023-12-15⁸³.
- 813

814 Data availability

- 815 Summary statistics (from the discovery analysis and the final meta-analysis) will be made
- 816 available in the NHGRI-EBI GWAS Catalog (https://www.ebi.ac.uk/gwas/downloads/summary-
- statistics). PRS weights (PRS₃₁₈, PRS₄₄₇, PRS_{CSx,disc}, PRS_{CSx,joint}) will be made available in the
- 818 PGS catalog (https://www.pgscatalog.org/). To protect individuals' privacy, complete GERA data
- are available upon approved applications to the Kaiser Permanente Research Bank Portal
- 820 (https://researchbank.kaiserpermanente.org/for-researchers). UKB data are available in the
- 821 UKB cloud-based Research Analysis Platform (https://www.ukbiobank.ac.uk). GTEx data were
- obtained from the GTEx portal (www.gtexportal.org) and can be obtained from dbGaP
- 823 Accession phs000424.v8.p2.
- 824

825 Code availability

- 826 Genome-wide association analysis were conducted using PLINK v2.0a3.7LM (http://www.cog-
- genomics.org/plink/2.0/). Meta-analysis were conducted with a custom-patched METAL v2011-
- 828 03-25 (https://genome.sph.umich.edu/wiki/METAL_Documentation) that prevents numerical
- precision loss (lines 633 and 635 of "Main.cpp" modified to the number 15 to output 15 digits
- precision"), and with MJAM v2022-08-05 (https://github.com/USCbiostats/hJAM/R). Imputation
- 831 was done via imputation servers (https://imputationserver.sph.umich.edu,
- 832 https://imputation.biodatacatalyst.nhlbi.nih.gov), Minimac3
- 833 (https://genome.sph.umich.edu/wiki/Minimac3), and IMPUTE2
- 834 (https://mathgen.stats.ox.ac.uk/impute/impute_v2.html). Analysis were also conducted in R,
- including v4.2.0 (https://cran.r-project.org/). FUMA was used for annotation
- 836 (https://fuma.ctglab.nl). Circos plots were generated using Circos v0.69-6
- 837 (https://fuma.ctglab.nl). The genome-wide PRS was conducted with PRS-CSx v2023-08-10
- 838 (https://github.com/getian107/PRScsx).
- 839

840 Acknowledgements

- 841 We thank the participants who generously agreed to participate in each cohort. This research is
- based in part on data from the Million Veteran Program (MVP), Office of Research and
- 843 Development, Veterans Health Administration, and was supported by the MVP017 Exemplar
- 844 Cancer Project. This research was conducted using the UKB resource under application
- number 14105. In addition, the All of Us Research Program would not be possible without the
- 846 partnership of its participants.
- 847

848 Funding

- 849 The Precision PSA study is supported by funding from the National Institutes of Health (NIH)
- 850 National Cancer Institute (NCI) under award number R01CA241410 (PI: JSW) and
- 851 U01CA261339 (MPI: JSW). LK is supported by funding from the National Cancer Institute

852 (R00CA246076). REG is supported by a Young Investigator Award from the Prostate Cancer 853 Foundation. HL is supported in part by NIH/NCI by a Cancer Center Support Grant to Memorial 854 Sloan Kettering Cancer Center (P30 CA008748, PI: Vickers, S), U01-CA266535 (PI: Carlsson, 855 S), R01-CA244948 (PI: RJK), and Swedish Cancer Society (Cancerfonden 20 1354 PJF; PI: 856 HL). This work was supported by research grants from the NIH National Institute of General 857 Medical Sciences (NIGMS) under award number R01GM130791 (PI: JDM); the computational 858 resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine 859 at Mount Sinai; the Office of Research Infrastructure of the National Institutes of Health under 860 award number S10OD026880 and NIH/NCI funding (R01CA175491, R01CA244948; PI: RJK); 861 the National Cancer Institute of the National Institutes of Health (UM1CA182883, PI: CM 862 Tangen/IM Thompson: U10CA37429, PI: CD Blanke). MADCaP was supported by 863 U01CA184374 (PI: TR). COMPASS was supported by P30CA014599. Support for GERA 864 participant enrollment, survey completion, and biospecimen collection for RPGEH was provided 865 by the Robert Wood Johnson Foundation, the Wayne and Gladys Valley Foundation, the Ellison 866 Medical Foundation, and Kaiser Permanente national and regional benefit programs. GERA 867 genotyping was funded by National Institute on Aging and NIH Common Fund (grant RC2 AG-868 036607 to Cathy Schaeffer and Neil Risch). The All of Us Research Program is supported by 869 the National Institutes of Health, Office of the Director: Regional Medical Centers: 1 OT2 870 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 871 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA #: 872 AOD 16037; Federally Qualified Health Centers: HHSN 263201600085U; Data and Research 873 Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176; 874 Participant Technology Systems Center: 1 U24 OD023163; Communications and Engagement: 3 OT2 OD023205; 3 OT2 OD023206; and Community Partners: 1 OT2 OD025277; 3 OT2 875 876 OD025315; 1 OT2 OD025337; 1 OT2 OD025276.

877

878 The content is solely the responsibility of the authors and does not necessarily represent the

879 official views of the National Institutes of Health. The funders had no role in study design, data

collection and analysis, the decision to publish, or preparation of the manuscript.

881

882 Conflict of Interest

JSW and CLC are non-employee co-founders of Avail Bio. HL is named on a patent for intact
PSA assays and a patent for a statistical method to detect prostate cancer that is licensed to
and commercialized by OPKO Health. HL receives royalties from sales of the test and has stock
in OPKO Health. REG consults for Hunton Andrews Kurth LLP on subject matter unrelated to
this study.

890 Figures and Tables

891 Figure 1. Flowchart describing the Precision PSA project analysis workflow and ancestry

892 compositions of the discovery, replication, and joint meta-analysis cohorts. The discovery

- 603 GWAS analysis revealed 318 genome-wide significant (p<5e-8) SNPs associated with PSA
- levels, of which 184 were novel. The joint analysis (consisting of the discovery and replication
- cohorts) revealed 447 genome-wide significant SNPs associated with PSA levels, of which an
- additional 111 were novel. Both discovery and joint GWAS results were used to develop PRSs
- for PSA, which were then evaluated in GERA (when out-of-sample), PCPT, and SELECT.



898 899

901 Figure 2. Circos plot showing PSA GWAS significant variants by chromosome from the

902 **discovery cohort.** Concentric tracks are colored based on results from individual ancestries,

903 with gray indicating results from the overall discovery meta-analysis. The top 100,000 GWAS

SNPs (with the smallest p-values) per ancestry are shown as points; larger circled points

905 indicate the 318 genome-wide significant variants (p<5e-8; 184 of which were novel) from the

overall discovery analysis in all ancestries. SNP density in 10Mbp bins from the overall analysis

907 is shown as a heatmap above the overall track. The outermost ring displays genes associated

908 with novel discovery PSA SNPs.



912 Figure 3. Manhattan plot showing results from the joint multi-ancestry meta-analysis of

913 the discovery (n=296,754) and replication (n=95,768) studies. Only genome-wide significant

- associations (p<5e-8) are plotted. The joint analysis detected 447 independent genome-wide
- 915 significant PSA-associated SNPs. These included 111 novel variants that were conditionally
- 916 independent from previous findings and the discovery only analyses in each study alone (
- 917 indicated by the circles). Gene labels are given for variants with CADD>15 and/or variants that918 are prostate tissue eQTLs.



922 Figure 4. Plot of the relationship between minor allele frequency and estimated effect

923 sizes for PSA GWAS significant variants. Each point represents one of the 447 independent

genome-wide significant SNPs identified in our mJAM multi-ancestry GWAS joint meta-analysis.

- 925 The SNP effect sizes are expressed in In(PSA) per minor allele. The curves indicate the
- 926 hypothetical detectable SNP effect sizes for a given minor allele frequency, assuming statistical
- 927 power of 80%, α =5e-8 (genome-wide significant), and the sample size of each of our
- 928 populations here (297,166 European ancestry, N=61,745 African ancestry, 6,967 Asian



929 ancestry, 26,644 Hispanic).

Figure 5. Variance in PSA levels explained by PRSs. We constructed PRSs for PSA from our
discovery cohorts to allow assessment in GERA and our PRS validation cohorts (PCPT and
SELECT). We also constructed PRSs from the joint meta-analysis of discovery and replication
cohorts, with assessment in our validation cohorts. The PRSs were based on the multi-ancestry
identified conditionally independent genome-wide significant variants using mJAM and on a
multi-ancestry genome-wide score using PRS-CSx. The genome-wide score generally
performed better than the genome-wide significant score. The variance explained by genome-

- 940 wide PRSs (A) was up to 16.9% in Europeans, 18.6% in Hispanics/Latinos, 9.5% in Africans,
- and 15.3% in East Asians, and **(B)** decreased as age increased.



AFR

EAS

942 943 944 5

0

EUR

F

Ancestry

945 **Figure 6. Biopsy reclassification with genetically-adjusted PSA.** PSA levels were adjusted

946 using the PRS-CSx estimate from the out-of-sample discovery cohort, assessed in GERA using

947 age-specific cutoffs in (A) Europeans and (B) African Americans (see Methods). GERA Latinos
948 and East Asians are shown in Figure S3.

Α



В



950 **References**

951

- Lilja, H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. *J Clin Invest* **76**, 1899–1903 (1985).
- Lilja, H., Ulmert, D. & Vickers, A. J. Prostate-specific antigen and prostate cancer:
 prediction, detection and monitoring. *Nat Rev Cancer* 8, 268–278 (2008).
- Balk, S. P., Ko, Y.-J. & Bubley, G. J. Biology of prostate-specific antigen. J Clin Oncol 21, 383–391 (2003).
- 4. Lilja, H., Ulmert, D. & Vickers, A. J. Prostate-specific antigen and prostate cancer:
 prediction, detection and monitoring. *Nat Rev Cancer* 8, 268–278 (2008).
- 960 5. Pinsky, P. F. *et al.* Prostate volume and prostate-specific antigen levels in men enrolled in a
 961 large screening trial. *Urology* 68, 352–356 (2006).
- 962
 6. Lee, S. E. *et al.* Relationship of prostate-specific antigen and prostate volume in Korean
 963 men with biopsy-proven benign prostatic hyperplasia. *Urology* **71**, 395–398 (2008).
- Grubb, R. L. *et al.* Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. *Cancer Epidemiol Biomarkers Prev* 18, 748–751 (2009).
- Harrison, S. *et al.* Systematic review and meta-analysis of the associations between body
 mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen.
 Cancer Causes Control **31**, 431–449 (2020).
- Jemal, A. *et al.* Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF
 Screening Recommendations. *JAMA* 314, 2054–2061 (2015).
- 10. Gulati, R., Inoue, L. Y. T., Gore, J. L., Katcher, J. & Etzioni, R. Individualized estimates of overdiagnosis in screen-detected prostate cancer. *J Natl Cancer Inst* **106**, djt367 (2014).
- 974 11. Sammon, J. D. *et al.* Prostate-Specific Antigen Screening After 2012 US Preventive
 975 Services Task Force Recommendations. *JAMA* 314, 2077–2079 (2015).
- Hugosson, J. *et al.* A 16-yr Follow-up of the European Randomized study of Screening for
 Prostate Cancer. *Eur Urol* **76**, 43–51 (2019).
- 978 13. Sandhu, G. S. & Andriole, G. L. Overdiagnosis of Prostate Cancer. J Natl Cancer Inst Monogr 2012, 146–151 (2012).
- 980 14. Frånlund, M. *et al.* Results from 22 years of Followup in the Göteborg Randomized
 981 Population-Based Prostate Cancer Screening Trial. *J Urol* 208, 292–300 (2022).
- 15. US Preventive Services Task Force. Screening for Prostate Cancer: US Preventive
 Services Task Force Recommendation Statement. *JAMA* 319, 1901–1913 (2018).

984 16. Bell, N. *et al.* Recommendations on screening for prostate cancer with the prostate-specific antigen test. *CMAJ* 186, 1225–1234 (2014).

- 17. Tikkinen, K. A. O. *et al.* Prostate cancer screening with prostate-specific antigen (PSA) test:
 a clinical practice guideline. *BMJ* 362, k3581 (2018).
- 18. Bansal, A. *et al.* Heritability of prostate-specific antigen and relationship with zonal prostate
 volumes in aging twins. *J Clin Endocrinol Metab* 85, 1272–1276 (2000).
- 990 19. Pilia, G. *et al.* Heritability of Cardiovascular and Personality Traits in 6,148 Sardinians. *PLoS* 991 *Genet* 2, e132 (2006).
- 20. Kachuri, L. *et al.* Genetically adjusted PSA levels for prostate cancer screening. *Nat Med*29, 1412–1423 (2023).
- Shen, J. *et al.* Fine-mapping and credible set construction using a multi-population joint analysis of marginal summary statistics. doi:https://doi.org/10.1101/2022.12.22.521659.
- 22. Kerem, B. S. *et al.* DNA marker haplotype association with pancreatic sufficiency in cystic
 fibrosis. *Am J Hum Genet* 44, 827–834 (1989).
- 23. Lippman, S. M. *et al.* Effect of selenium and vitamin E on risk of prostate cancer and other
 cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *JAMA* 301, 39–51

1000 (2009).

- 1001 24. Thompson, I. M. *et al.* Assessing prostate cancer risk: results from the Prostate Cancer
 1002 Prevention Trial. *J Natl Cancer Inst* 98, 529–534 (2006).
- 1003 25. Mayo, K. R. *et al.* The All of Us Data and Research Center: Creating a Secure, Scalable,
 1004 and Sustainable Ecosystem for Biomedical Research. *Annu Rev Biomed Data Sci* 6, 443–
 1005 464 (2023).
- Preston, M. A. *et al.* Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal
 Prostate Cancer. *J Clin Oncol* 34, 2705–2711 (2016).
- 1008
 1009
 1009
 1009
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010
 1010</l
- 1011 28. Dudbridge, F. *et al.* Adjustment for index event bias in genome-wide association studies of subsequent events. *Nat Commun* **10**, 1561 (2019).
- 1013 29. Jiang, L., Zheng, Z., Fang, H. & Yang, J. A generalized linear mixed model association tool
 1014 for biobank-scale data. *Nat Genet* 53, 1616–1621 (2021).
- 1015 30. Eldjarn, G. H. *et al.* Large-scale plasma proteomics comparisons through genetics and disease associations. *Nature* 622, 348–358 (2023).
- 1017 31. Kim, J. & Coetzee, G. A. Prostate specific antigen gene regulation by androgen receptor. J
 1018 Cell Biochem 93, 233–241 (2004).
- 1019 32. Heinlein, C. A. & Chang, C. Androgen Receptor in Prostate Cancer. *Endocrine Reviews* 25, 276–308 (2004).
- 33. Agúndez, J. A. G. *et al.* The diamine oxidase gene is associated with hypersensitivity
 response to non-steroidal anti-inflammatory drugs. *PLoS One* 7, e47571 (2012).
- 1023 34. Amo, G. *et al.* FCERI and Histamine Metabolism Gene Variability in Selective Responders
 1024 to NSAIDS. *Front Pharmacol* 7, 353 (2016).
- 35. Miller, C. L. *et al.* Integrative functional genomics identifies regulatory mechanisms at coronary artery disease loci. *Nat Commun* 7, 12092 (2016).
- 1027 36. Linseman, T. *et al.* Functional Validation of a Common Nonsynonymous Coding Variant in
 1028 ZC3HC1 Associated With Protection From Coronary Artery Disease. *Circ Cardiovasc Genet* 1029 10, e001498 (2017).
- 37. Cuppens, H. & Cassiman, J.-J. CFTR mutations and polymorphisms in male infertility. *Int J* Androl 27, 251–256 (2004).
- 1032 38. Landrum, M. J. *et al.* ClinVar: improvements to accessing data. *Nucleic Acids Research* 48, D835–D844 (2020).
- 39. Kawa, S. *et al.* Azoospermia in mice with targeted disruption of the Brek/Lmtk2 (brainenriched kinase/lemur tyrosine kinase 2) gene. *Proc Natl Acad Sci U S A* **103**, 19344–
 19349 (2006).
- 40. Cruz, D. F., Farinha, C. M. & Swiatecka-Urban, A. Unraveling the Function of Lemur
 Tyrosine Kinase 2 Network. *Frontiers in Pharmacology* **10**, (2019).
- 41. Bostwick, D. G. *et al.* The association of benign prostatic hyperplasia and cancer of the prostate. *Cancer* **70**, 291–301 (1992).
- 42. Ørsted, D. D. & Bojesen, S. E. The link between benign prostatic hyperplasia and prostate cancer. *Nat Rev Urol* 10, 49–54 (2013).
- 1043 43. Thompson, I. M. *et al.* Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. *N Engl J Med* **350**, 2239–2246 (2004).
- 44. Coric, J., Mujic, J., Kucukalic, E. & Ler, D. Prostate-Specific Antigen (PSA) and Prostate
 Volume: Better Predictor of Prostate Cancer for Bosnian and Herzegovina Men. *Open Biochem J* 9, 34–36 (2015).
- 1048 45. D'Amico, A. V. Risk-based management of prostate cancer. *N Engl J Med* **365**, 169–171 (2011).

- 1050 46. R Core Team. R: A language and environment for statistical computing. (2012).
- 47. McGrath, S., Zhao, X., Qin, Z. Z., Steele, R. & Benedetti, A. One-sample aggregate data
 meta-analysis of medians. *Statistics in Medicine* 38, 969–984 (2019).
- 48. Tayo, B. O. *et al.* Genetic background of patients from a university medical center in
 Manhattan: implications for personalized medicine. *PLoS One* 6, e19166 (2011).
- 49. Aschebrook-Kilfoy, B. *et al.* Cohort profile: the ChicagO Multiethnic Prevention and
 Surveillance Study (COMPASS). *BMJ Open* **10**, e038481 (2020).
- 1057 50. Press, D. J. *et al.* Tobacco and marijuana use and their association with serum prostate1058 specific antigen levels among African American men in Chicago. *Prev Med Rep* 20, 101174 (2020).
- 1060 51. Andrews, C. *et al.* Development, Evaluation, and Implementation of a Pan-African Cancer
 1061 Research Network: Men of African Descent and Carcinoma of the Prostate. *J Glob Oncol* 4, 1–14 (2018).
- 1063 52. Harlemon, M. *et al.* A Custom Genotyping Array Reveals Population-Level Heterogeneity for
 1064 the Genetic Risks of Prostate Cancer and Other Cancers in Africa. *Cancer Res* 80, 2956–
 1065 2966 (2020).
- 1066 53. Kolonel, L. N., Altshuler, D. & Henderson, B. E. The multiethnic cohort study: exploring genes, lifestyle and cancer risk. *Nat Rev Cancer* 4, 519–527 (2004).
- 1068 54. Kolonel, L. N. *et al.* A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics.
 1069 *Am. J. Epidemiol.* **151**, 346–357 (2000).
- 55. Gaziano, J. M. *et al.* Million Veteran Program: A mega-biobank to study genetic influences
 on health and disease. *J Clin Epidemiol* **70**, 214–223 (2016).
- 1072 56. Fang, H. *et al.* Harmonizing Genetic Ancestry and Self-identified Race/Ethnicity in Genome 1073 wide Association Studies. *The American Journal of Human Genetics* **105**, 763–772 (2019).
- 1074 57. Signorello, L. B. *et al.* Southern community cohort study: establishing a cohort to investigate
 1075 health disparities. *J Natl Med Assoc* 97, 972–979 (2005).
- 1076 58. Venner, E. *et al.* The frequency of pathogenic variation in the All of Us cohort reveals
 1077 ancestry-driven disparitie. Preprint at https://doi.org/10.1101/2022.12.19.22283658 (2022).
- 1078 59. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program | Nature.
 1079 https://www.nature.com/articles/s41586-021-03205-y.
- 1080 60. Das, S. *et al.* Next-generation genotype imputation service and methods. *Nat Genet* 48, 1284–1287 (2016).
- 1082 61. Howie, B., Fuchsberger, C., Stephens, M., Marchini, J. & Abecasis, G. R. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. *Nat Genet*1084 44, 955–959 (2012).
- 1085 62. 1000 Genomes Project Consortium *et al.* A global reference for human genetic variation.
 1086 Nature 526, 68–74 (2015).
- 1087 63. Consortium, T. 1000 G. P. A map of human genome variation from population-scale
 1088 sequencing. *Nature* 467, 1061–1073 (2010).
- 1089 64. Sheng, X. *et al.* Inverted genomic regions between reference genome builds in humans impact imputation accuracy and decrease the power of association testing. *HGG Adv* 4, 1091 100159 (2023).
- 1092 65. Karolchik, D. *et al.* The UCSC Genome Browser database: 2014 update. *Nucl. Acids Res.* 1093 42, D764–D770 (2014).
- 66. Ganesh, S. K. *et al.* Effects of Long-Term Averaging of Quantitative Blood Pressure Traits
 on the Detection of Genetic Associations. *The American Journal of Human Genetics* 95, 49–
 65 (2014).
- 1097 67. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* 26, 2190–2191 (2010).
- 1099 68. Hoffmann, T. J. *et al.* Genome-wide association study of prostate-specific antigen levels

- identifies novel loci independent of prostate cancer. *Nat Commun* **8**, 14248 (2017).
- 1101 69. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. *Nat Commun* **8**, 1826 (2017).
- 1103 70. Kircher, M. *et al.* A general framework for estimating the relative pathogenicity of human genetic variants. *Nat Genet* **46**, 310–315 (2014).
- 1105 71. O'Leary, N. A. *et al.* Reference sequence (RefSeq) database at NCBI: current status,
 1106 taxonomic expansion, and functional annotation. *Nucleic Acids Res* 44, D733-745 (2016).
- 1107 72. Krzywinski, M. *et al.* Circos: an information aesthetic for comparative genomics. *Genome* 1108 *Res* 19, 1639–1645 (2009).
- 73. Gerstenbluth, R. E., Maniam, P. N., Corty, E. W. & Seftel, A. D. Prostate-specific antigen
 changes in hypogonadal men treated with testosterone replacement. *J Androl* 23, 922–926
 (2002).
- 1112 74. Guess, H. A., Heyse, J. F. & Gormley, G. J. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. *Prostate* 22, 31–37 (1993).
- 1114 75. Ruan, Y. *et al.* Improving polygenic prediction in ancestrally diverse populations. *Nat Genet*54, 573–580 (2022).
- 76. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets. *GigaScience* 4, (2015).
- 1118 77. Oesterling, J. E. *et al.* Serum prostate-specific antigen in a community-based population of
 1119 healthy men. Establishment of age-specific reference ranges. *JAMA* 270, 860–864 (1993).
- 78. W. N. Ripley & B. D. Ripley. *Modern Applied Statistics with S.* (Springer, New York, NY, USA, 2002).
- 1122 79. Kuhn, M. Building Predictive Models in R Using the caret Package. *Journal of Statistical*1123 Software 28, 1–26 (2008).
- 1124 80. Barry, M. J. *et al.* The American Urological Association Symptom Index for Benign Prostatic 1125 Hyperplasia. *J Urol* **197**, S189–S197 (2017).
- 1126 81. Newcomb, L. F. *et al.* Canary Prostate Active Surveillance Study: design of a multi-1127 institutional active surveillance cohort and biorepository. *Urology* **75**, 407–413 (2010).
- 1128 82. Jiang, Y. *et al.* Genetic Factors Associated with Prostate Cancer Conversion from Active
 1129 Surveillance to Treatment. *HGG Adv* 3, 100070 (2022).
- 83. Program, C. S.-C. B. *et al.* CZ CELL×GENE Discover: A single-cell data platform for
 scalable exploration, analysis and modeling of aggregated data. 2023.10.30.563174
 Preprint at https://doi.org/10.1101/2023.10.30.563174 (2023).
- 1133
- 1134